Page 76 - Zai Lab News Today

Press release content from PR Newswire. The AP news staff was not involved in its creation.

-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout...

PRTK earnings call for the period ending June 30, 2021.

Peruinforma Desarrollará soluciones de Inteligencia Artificial que aumentarán la eficiencia y la sostenibilidad de empresas, administraciones públicas y la sociedad, con impacto real en aspectos como salud y calidad de vida, economía circular, democratización del e-commerce, optimización de procesos industriales, empleo inteligente o educación AI Lab Granada contará con más de 100 doctores en Inteligencia Artificial, 165 consultores, desarrolladores e inve...

Taiwan Business TOPICS Local pharmaceutical firm Golden Biotechnology Corp. independently developed Antroquinonol (Hocena®), a novel small-molecule drug, and is now testing its use for treatment of COVID-19. Photo: Golden Biotechnology Corp. Despite rigorous border control and strict measures, COVID-19 has made its way into Taiwan. Now businesses, researchers, and government are working on innovations that will put Taiwan back in business. Until recently, Taiwan had a remarkable succ...

Amgen today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers . New data includes median overall survival a secondary endpoint that was reached with longer ...

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an...

socaltech.com San Diego-based oncology therapeutics developer Mirati Therapeutics said this morning that it has received $65M in an upfront payment, as part of a deal with Chinese company Zai Lab. According to the to companies,t he two have entered into a collaboration to develop and commercialize Miratis Adagrasib in Greater China. Mirati will receive $65M upfront, with up to approximately $273M in potential milestone payments and royalties. Charles M. Baum, M.D., Ph.D., is President and CEO...

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib May 28, 2021 07:30 ET | Source: Zai Lab Limited Zai Lab Limited TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first p...

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that ...